Compositions and methods for modulation of extracellular vesicle release and treatment of neurological disorders
This disclosure relates to methods and compositions for inhibiting release of extracellular vesicles from a cell infected by a virus. One aspect of the disclosure relates to methods for treating viral diseases, reducing damage to a neuron from the central neural system (“CNS”) and/or treating neuroinflammation in a subject. In another aspect, provided herein are methods for inhibiting transcription of a viral RNA and/or release of extracellular vesicles from a cell infected by a virus.
1. A pharmaceutical composition comprising a cannabinoid product in an effective amount sufficient to inhibit release of extracellular vesicles from a cell infected by a virus, wherein the cell is a neuron, an astrocyte, an oligodendrocyte, or a microglia, and wherein the virus is a human immunodeficiency virus (HIV) or a human T-cell leukemia-lymphoma virus (HTLV).
2. The pharmaceutical composition of claim 1 , further comprising azidothymidine, an interferon (“IFN”), a tetracycline antibiotic, or the combination thereof.
3. The pharmaceutical composition of claim 1 , wherein the cannabinoid product comprises a pentyl side chain on an aromatic ring or a propyl side chain on an aromatic ring.
4. The pharmaceutical composition of claim 1 , wherein the cannabinoid product comprises tetrahydrocannabinol (THC), cannabidiol (CBD), olivetol, cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabicyclol (CBCL), nabilone, tetrahydrocannabinolic acid (THCA), cannabichromenic acid (CBCA), cannabicyclolic acid (CBCLA), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), cannabinolic acid (CBNA), tetrahydrocannabivarin (THCV), cannabivarin (CBV), cannabidivarin (CBDV), cannabigerovarin (CBGV), cannabichromevarin (CBCV), cannabicyclovarin (CBCLV), cannabicyclovarinic acid (CBCLVA), cannabigerovarinic acid (CBGVA), tetrahydrocannabivarinic acid (THCVA), cannabichrome varinic acid (CBCVA), cannabidivarinic acid (CBDVA), or a combination thereof.
5. The pharmaceutical composition of claim 1 , wherein the cannabinoid compound comprises CBD, THC, or a combination thereof.
6. The pharmaceutical composition of claim 2 , wherein the IFN comprises IFN-α, IFN-β, IFN-ε, IFN-κ, IFN-ω, IFN-γ, IFN-λ1, IFN-λ2, and IFN-λ3; and wherein the tetracycline antibiotic comprises tetracycline, chlortetracycline, oxytetracycline, demeclocycline, doxycycline, lymecycline, meclocycline, methacycline, minocycline, rolitetracycline, tigecycline, or a combination thereof.
7. The pharmaceutical composition of claim 1 further comprising azidothymidine, an interferon (“IFN”), a tetracycline antibiotic, an anti-inflammatory agent, a neurotrophic factor, a neuroprotective agent, or a combination thereof.
8. The pharmaceutical composition of claim 7 , wherein the anti-inflammatory agent is GFβ, IL-2, IL-17, IL-35, or IL-37; and wherein the neurotrophic factor is BDNF, NGF, Neurotrophin-3, FGF2, CTNF, GDNF, IGF2, HGF, Noggin, or T3.
9. The pharmaceutical composition of claim 1 , further comprises a pharmaceutically acceptable carrier.
10. A method for treating a viral disease in a subject in need thereof, comprising
administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a cannabinoid product in an effective amount sufficient to inhibit release of extracellular vesicles from a cell infected by a virus,
wherein the cell is a neuron, an astrocyte, an oligodendrocyte, or a microglia, and
wherein the virus is a human immunodeficiency virus (HIV) or a human T-cell leukemia-lymphoma virus (HTLV).
11. The method of claim 10 , wherein the viral disease is a neurological disorder; is associated with HIV-1 and/or HTLV-1; or comprises Alzheimer's disease, multiple sclerosis, stroke, or a combination thereof.
12. The method of claim 11 , wherein the neurological disorder comprises viral meningitis, viral encephalitis, postherpetic neuralgia, HIV-associated neurocognitive disorders, HTLV-1 associated myelopathy, poliomyelitis, influenza, Reye's Syndrome, Meniere's Disease, trigeminal neuralgia, or herpes zoster.
13. The method of claim 12 , wherein the HIV-associated neurocognitive disorder comprises asymptomatic neurocognitive impairment (ANI), minor neurocognitive disorder (MND), minor cognitive motor disorder (MCMD), HIV-associated dementia (HAD), HIV-associated myelopathy, HIV-associated peripheral neuropathy, or a combination thereof.
14. A method of reducing damage to a neuron from central neural system (“CNS”) or treating neuroinflammation in a subject in need thereof, comprising
administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a cannabinoid product in an effective amount sufficient to inhibit release of extracellular vesicles from a cell infected by a virus,
wherein the cell is a neuron, an astrocyte, an oligodendrocyte, or a microglia, and
wherein the virus is a human immunodeficiency virus (HIV) or a human T-cell leukemia-lymphoma virus (HTLV).
15. The method of claim 14 , wherein the damage is caused by infection of the subject with a HIV and/or HTLV-1.
16. A method of inhibiting transcription of a viral RNA comprising contacting the cell with the pharmaceutical composition of claim 1 .
17. A method of inhibiting release of extracellular vesicles from a cell infected by a virus, comprising contacting the cell with the pharmaceutical composition of claim 1 .
18. The method of claim 17 , wherein the extracellular vesicles comprise an exosome and/or a microvesicle.